Answers are grounded in this paper and cite their sources.
Phase Ib study shows promising efficacy and manageable adverse events in relapsed/refractory B-cell lymphoma patients receiving Mosun or Glofit with Golca.
Background: Mosun and Glofit, both CD20xCD3 T-cell engaging bispecific antibodies, have demonstrated high response rates and manageable safety in patients (pts) with R/R follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Golca, a CELMoDTM agent, drives the closed active conformation of cereblon inducing rapid degradation of Ikaros and Aiolos, and has shown promising efficacy and a manageable safety profile. We report preliminary safety and efficacy data from a Phase Ib study (NCT05169515) of Golca combined with Mosun (Arm 1) or Glofit (Arm 2) in pts with R/R B-NHL. Methods: Pts with R/R B-NHL (DLBCL, FL Grade [Gr]1–3a, transformed [tr]FL) received treatment for up to 12 cycles. In Arm 1, subcutaneous Mosun was given with step-up dosing in Cycle (C)1 (Day [D]1, 5mg; D8 and D15, 45mg; 21-day cycle), then 45mg on D1 of subsequent cycles (28-day cycles); concurrently, oral Golca (0.1, 0.2, or 0.4mg) was given daily from C1 or C2 onwards (D1–14; 28-day cycles). In Arm 2, pts received intravenous obinutuzumab pretreatment on C1D1 and Glofit on C1D8 (2.5mg), D15 (10mg), then D1 of subsequent cycles (30mg); oral Golca was given daily from C2 or C3 onwards (D1–10; 21-day cycles) in dose escalation (0.2 or 0.4mg). Prophylactic G-CSF was mandatory for the first cycle of combination therapy. Primary endpoints were safety including DLTs and Golca RP2D selection. Secondary endpoints included investigator-assessed overall response rate (ORR) and complete response rate (CRR; Lugano 2014 criteria). Results: As of May 5, 2025, 35 (10 DLBCL; 20 FL; 4 trFL; 1 composite FL/DLBCL) and 12 (3 DLBCL; 9 FL) pts were enrolled in Arms 1 and 2, respectively (safety-evaluable population). In Arms 1 and 2, median age was 63 (range: 30–83) and 60 years (range: 37–76), 29% and 42% of pts had prior CAR T-cell therapy, respectively. Median number of prior therapies was 3 (range: 1–6) in Arm 1 and 2 (range: 1–4) in Arm 2. Gr ≥3 AEs occurred in 74% and 67% of pts in Arms 1 and 2, respectively; there were no Gr 5 AEs. Serious AEs occurred in 66% of pts in Arm 1 and 50% of pts in Arm 2. Most common AEs in Arms 1 and 2, respectively, were neutropenia (Gr ≥3: 57% and 58%), injection site reactions (57%; all Gr 1/2 in Arm 1 only), CRS (Gr 1/2: 43% and 33%, no Gr ≥3), rash (Gr ≥3: 3% and 0%), and infections (Gr ≥3: 11% and 8%). Gr ≥3 neurological AEs occurred in 3% of pts (n=1; Gr 3 presyncope) in Arm 1 and 17% of pts (n=2; Gr 3 cognitive disorder and Gr 4 spinal cord compression) in Arm 2. ICANS as a preferred term was reported in one patient in Arm 2 (Gr 2); suspected ICANS was observed in 11% of pts (all Gr 1: cognitive disorder, n=1; lethargy, n=1; syncope, n=2) in Arm 1 and 17% of pts (Gr 3 cognitive disorder, n=1; Gr 1/2 somnolence, n=1) in Arm 2. Febrile neutropenia (FN) occurred in 11% of pts in Arm 1 and 8% of pts in Arm 2. AEs leading to treatment discontinuation occurred in 17% of pts (neutropenia, n=3; anemia, disseminated intravascular coagulation, and thrombocytopenia, n=1 each) in Arm 1 and none in Arm 2. DLTs were reported in 3 pts in Arm 1 (Golca 0.2mg, Gr 3 FN and herpes zoster; Golca 0.1mg, Gr 3 rash) and one patient in Arm 2 (Golca 0.4mg, Gr 3 FN). In efficacy-evaluable pts (Arm 1, n=27 [14 FL; 13 DLBCL/trFL]; Arm 2, n=10 [8 FL; 2 DLBCL/trFL]), responses were observed at all Golca doses in both arms. In Arm 1, the ORR and CRR were 70% and 44%, respectively. In pts with FL, the ORR and CRR were 79% and 43%, and in DLBCL/trFL, 62% and 46%, respectively. At the 0.4mg dose of Golca (n=7), 4/4 pts with FL had a CR, 2/3 pts with DLBCL/trFL had a partial response (PR). In Arm 2, the ORR and CRR were 90% and 70%, respectively. In 8 pts with FL, the ORR was 88% (7/8), CRR was 75% (6/8). Of the 2 pts with DLBCL/trFL, one had a CR, one a PR. Median time to first response was 2.6 months (range: 2–4) in Arm 1 and 1.9 months (range: 1–3) in Arm 2. Ikaros degradation in peripheral T cells was observed at 0.2 and 0.4mg doses of Golca. Conclusions: Early data suggest Mosun/Glofit+Golca is an active regimen with a manageable safety profile consistent with the risks of individual agents. No new safety signals were observed; CRS events were low grade. Neutropenia was the most common overlapping toxicity and was manageable with prophylactic and therapeutic G-CSF. ICANS as a preferred term was low grade and occurred in one patient. This novel combination therapy showed activity in heavily pretreated pts with B-NHL and warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Avivi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: